gene	variant_upper	protein_start	protein_end	id	entrez_id	variant	disease	doid	phenotypes	drugs	drug_interaction_type	evidence_type	evidence_direction	evidence_level	clinical_significance	evidence_statement	citation_id	source_type	asco_abstract_id	citation	nct_ids	rating	evidence_status	evidence_id	variant_id	gene_id	chromosome	start	stop	reference_bases	variant_bases	representative_transcript	chromosome2	start2	stop2	representative_transcript2	ensembl_version	reference_build	variant_summary	variant_origin	last_review_date	evidence_civic_url	variant_civic_url	gene_civic_url	is_flagged
EGFR	EXON 20 INSERTION	762	823	1612	1956	Exon 20 Insertion	Lung Adenocarcinoma	3910	NA	Afatinib	NA	Predictive	Supports	B	Resistance	In retrospective analysis of trials, afatinib conferred limited clinical benefit to patients with EGFR exon 20 insertion mutations (N=23). Only 2 patients had objective responses.	26051236	PubMed	NA	Yang et al., 2015, Lancet Oncol.	NCT00525148,NCT00949650,NCT01121393	3	accepted	1809	726	19	7	55248991	55249022	NA	NA	ENST00000275493.2	NA	NA	NA	NA	75	GRCh37	NA	Somatic	2020-08-12 15:43:10 UTC	https://civic.genome.wustl.edu/links/evidence_items/1809	https://civic.genome.wustl.edu/links/variants/726	https://civic.genome.wustl.edu/links/genes/19	FALSE
EGFR	EXON 20 INSERTION	762	823	2384	1956	Exon 20 Insertion	Lung Adenocarcinoma	3910	NA	Erlotinib	NA	Predictive	Supports	C	Resistance	In stage IV lung adenocarcinoma patients (n=2) harboring EGFR inframe exon 20 insertion mutation, EGFR exon 20 insertion was associated with progressive disease after 1 and 3 months of erlotinib monotherapy, respectively; both patients were previously treated with standard chemotherapy.	22895145	PubMed	NA	Lund-Iversen et al., 2012, J Thorac Oncol	NA	NA	accepted	4650	726	19	7	55248991	55249022	NA	NA	ENST00000275493.2	NA	NA	NA	NA	75	GRCh37	NA	Somatic	2020-08-12 15:43:10 UTC	https://civic.genome.wustl.edu/links/evidence_items/4650	https://civic.genome.wustl.edu/links/variants/726	https://civic.genome.wustl.edu/links/genes/19	FALSE
ERBB2	EXON 20 INSERTION	770	831	3888	2064	Exon 20 Insertion	Lung Non-small Cell Carcinoma	3908	NA	Trastuzumab Deruxtecan	NA	Predictive	Supports	B	Sensitivity/Response	In a phase 2 trial, 91 patients with ERBB2-mutant metastatic non-small-cell lung cancer, refractory to standard treatment, were treated with trastuzumab deruxtecan. The objective response was 55% (95% CI, 44 to 65), the median duration of response was 9.3 months (95% CI 5.7 to 14.7), the median PFS was 8.2 months (95% CI 6.0 to 11.9), and the median OS was 17.8 months (95% CI 13.8 to 22.1). 81 of 91 patients had an Exon 20 Insertion mutation and 46 of 78 evaluable patients with this mutation type had a partial response (PR).	34534430	PubMed	NA	Li et al., 2022, N Engl J Med	NCT03505710	5	accepted	10140	2854	20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Somatic	2022-03-01 20:06:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/10140	https://civic.genome.wustl.edu/links/variants/2854	https://civic.genome.wustl.edu/links/genes/20	FALSE
